Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma. Anaplastic large cell lymphoma is made up of either malignant T-cells (type of cells in the immune system), or null-lymphocytes (lack both B or T-cell markers). The presence of the protein, ‘CD30 antigen’ on the surface of lymphoma cells is a distinctive feature of the ALCL. ALCL occurs in two forms, systemic ALCL and primary cutaneous ALCL. Systemic ALCL can affect all organs in the body and it is aggressive while primary cutaneous ALCL is confined to the skin and tends to be slow-growing. There are two sub-types of anaplastic large cell lymphoma known as, ALK-negative and ALK-positive, depending on whether the lymphoma cells produce a protein called ‘anaplastic large cell kinase’ (ALK). People with ALK-positive ALCL are generally younger and respond better to treatment, as compared to the patients diagnosed with ALK-negative ALCL.
The drug candidates of anaplastic large cell lymphoma pipeline include, but are not limited to, TAK228, and KIR3DL2. Also, some of the companies having drug candidates in the anaplastic large cell lymphoma pipeline include Ariad Pharmaceuticals, Inc., AstraZeneca plc, and Bayer AG.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.